Although, the GnRH-ant protocol should be preferred in the presumed high-risk OHSS patients [17], identifying high-risk patients remains an unsolved issue, and a formal consensus defining a patient as a “hyper-responder” is currently lacking. This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.